JP5870088B2 - 共役血液凝固第viii因子 - Google Patents

共役血液凝固第viii因子 Download PDF

Info

Publication number
JP5870088B2
JP5870088B2 JP2013506735A JP2013506735A JP5870088B2 JP 5870088 B2 JP5870088 B2 JP 5870088B2 JP 2013506735 A JP2013506735 A JP 2013506735A JP 2013506735 A JP2013506735 A JP 2013506735A JP 5870088 B2 JP5870088 B2 JP 5870088B2
Authority
JP
Japan
Prior art keywords
fviii
group
pharmaceutical composition
composition according
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013506735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525414A (ja
JP2013525414A5 (enExample
Inventor
ヘンリー,ウィリアム
Original Assignee
カンタブ バイオファーマシューティカルズ パテンツ リミテッド
カンタブ バイオファーマシューティカルズ パテンツ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5870088(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by カンタブ バイオファーマシューティカルズ パテンツ リミテッド, カンタブ バイオファーマシューティカルズ パテンツ リミテッド filed Critical カンタブ バイオファーマシューティカルズ パテンツ リミテッド
Publication of JP2013525414A publication Critical patent/JP2013525414A/ja
Publication of JP2013525414A5 publication Critical patent/JP2013525414A5/ja
Application granted granted Critical
Publication of JP5870088B2 publication Critical patent/JP5870088B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2013506735A 2010-04-30 2011-04-28 共役血液凝固第viii因子 Expired - Fee Related JP5870088B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
GB1007357.5 2010-04-30
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii

Publications (3)

Publication Number Publication Date
JP2013525414A JP2013525414A (ja) 2013-06-20
JP2013525414A5 JP2013525414A5 (enExample) 2014-06-19
JP5870088B2 true JP5870088B2 (ja) 2016-02-24

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013506735A Expired - Fee Related JP5870088B2 (ja) 2010-04-30 2011-04-28 共役血液凝固第viii因子

Country Status (26)

Country Link
US (1) US20130150302A1 (enExample)
EP (1) EP2563402A1 (enExample)
JP (1) JP5870088B2 (enExample)
KR (1) KR20130055619A (enExample)
CN (1) CN102939108A (enExample)
AP (1) AP2012006575A0 (enExample)
AU (1) AU2011247147B2 (enExample)
BR (1) BR112012027590A2 (enExample)
CA (1) CA2797058A1 (enExample)
CL (1) CL2012003039A1 (enExample)
CO (1) CO6660443A2 (enExample)
CR (1) CR20120579A (enExample)
EA (1) EA201290938A1 (enExample)
EC (1) ECSP12012314A (enExample)
GB (2) GB201007357D0 (enExample)
IL (1) IL222566A (enExample)
MX (1) MX2012012683A (enExample)
MY (1) MY160922A (enExample)
NI (1) NI201200160A (enExample)
NZ (1) NZ603939A (enExample)
PE (1) PE20130254A1 (enExample)
PH (1) PH12012502150A1 (enExample)
RU (1) RU2012144555A (enExample)
SG (1) SG184906A1 (enExample)
WO (1) WO2011135307A1 (enExample)
ZA (1) ZA201208989B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
EA033469B1 (ru) 2012-04-16 2019-10-31 Cantab Biopharmaceuticals Patents Ltd Подкожное введение конъюгатов факторов крови с полиэтиленгликолем
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
KR102575788B1 (ko) 2018-05-18 2023-09-08 정저우 젠사이언시스 인코포레이티드 개선된 fviii 융합 단백질 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2572733A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
LT1824988T (lt) * 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
PL1835938T3 (pl) * 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
KR20110016440A (ko) * 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
CN102099058B (zh) * 2008-07-21 2014-10-22 宝力泰锐克斯有限公司 用于缀合生物分子的新试剂和方法
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
GB2492935B8 (en) 2014-10-29
BR112012027590A2 (pt) 2016-08-09
SG184906A1 (en) 2012-11-29
CA2797058A1 (en) 2011-11-03
MY160922A (en) 2017-03-31
GB2492935A (en) 2013-01-16
MX2012012683A (es) 2013-04-03
CL2012003039A1 (es) 2014-01-24
JP2013525414A (ja) 2013-06-20
HK1173946A1 (en) 2013-05-31
WO2011135307A1 (en) 2011-11-03
IL222566A (en) 2017-12-31
KR20130055619A (ko) 2013-05-28
PH12012502150A1 (en) 2013-02-04
RU2012144555A (ru) 2014-06-10
GB201220667D0 (en) 2013-01-02
PE20130254A1 (es) 2013-03-16
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
AP2012006575A0 (en) 2012-12-31
CR20120579A (es) 2013-04-25
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB2492935B (en) 2014-04-30
GB201007357D0 (en) 2010-06-16
IL222566A0 (en) 2012-12-31
AU2011247147B2 (en) 2014-09-18
NZ603939A (en) 2013-08-30
CO6660443A2 (es) 2013-04-30
CN102939108A (zh) 2013-02-20
EP2563402A1 (en) 2013-03-06
ZA201208989B (en) 2014-02-26
NI201200160A (es) 2013-04-19
ECSP12012314A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
JP5870088B2 (ja) 共役血液凝固第viii因子
CN102971013B (zh) 缀合的凝血因子VIIa
AU2009239641B2 (en) Factor IX conjugates with extended half-lives
JP2008525491A (ja) ポリマー−フォンビルブラント因子結合体
Shi et al. Site-specific PEGylation of human growth hormone by mutated sortase A
WO2024077335A1 (en) Factor ix variant polypeptides for administration to soft tissue
AU2015222846B2 (en) Peptides and methods of use
JP7094223B2 (ja) 病的な筋肉減少および筋力低下の処置のためのnope
HK1127300A (en) Pegylated factor viii
HK1151986B (en) Factor ix conjugates with extended half-lives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160108

R150 Certificate of patent or registration of utility model

Ref document number: 5870088

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees